Literature DB >> 19216838

Axitinib treatment in patients with cytokine-refractory metastatic renal cell cancer.

Ronald M Bukowski.   

Abstract

Entities:  

Year:  2009        PMID： 19216838     DOI： 10.1007/s11912-009-0013-7

Source DB:  PubMed          Journal:  Curr Oncol Rep        ISSN： 1523-3790            Impact factor:   5.075


× No keyword cloud information.
  8 in total

Review 1.  Role of VHL gene mutation in human cancer.

Authors:  William Y Kim; William G Kaelin
Journal:  J Clin Oncol       Date:  2004-12-15       Impact factor: 44.544

2.  Rapid vascular regrowth in tumors after reversal of VEGF inhibition.

Authors:  Michael R Mancuso; Rachel Davis; Scott M Norberg; Shaun O'Brien; Barbara Sennino; Tsutomu Nakahara; Virginia J Yao; Tetsuichiro Inai; Peter Brooks; Bruce Freimark; David R Shalinsky; Dana D Hu-Lowe; Donald M McDonald
Journal:  J Clin Invest       Date:  2006-10       Impact factor: 14.808

3.  Sorafenib in advanced clear-cell renal-cell carcinoma.

Authors:  Bernard Escudier; Tim Eisen; Walter M Stadler; Cezary Szczylik; Stéphane Oudard; Michael Siebels; Sylvie Negrier; Christine Chevreau; Ewa Solska; Apurva A Desai; Frédéric Rolland; Tomasz Demkow; Thomas E Hutson; Martin Gore; Scott Freeman; Brian Schwartz; Minghua Shan; Ronit Simantov; Ronald M Bukowski
Journal:  N Engl J Med       Date:  2007-01-11       Impact factor: 91.245

4.  Sunitinib versus interferon alfa in metastatic renal-cell carcinoma.

Authors:  Robert J Motzer; Thomas E Hutson; Piotr Tomczak; M Dror Michaelson; Ronald M Bukowski; Olivier Rixe; Stéphane Oudard; Sylvie Negrier; Cezary Szczylik; Sindy T Kim; Isan Chen; Paul W Bycott; Charles M Baum; Robert A Figlin
Journal:  N Engl J Med       Date:  2007-01-11       Impact factor: 91.245

Review 5.  Biology and clinical development of vascular endothelial growth factor-targeted therapy in renal cell carcinoma.

Authors:  Brian I Rini; Eric J Small
Journal:  J Clin Oncol       Date:  2004-11-08       Impact factor: 44.544

6.  Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results.

Authors:  Hope S Rugo; Roy S Herbst; Glenn Liu; John W Park; Merrill S Kies; Heidi M Steinfeldt; Yazdi K Pithavala; Steven D Reich; James L Freddo; George Wilding
Journal:  J Clin Oncol       Date:  2005-07-18       Impact factor: 44.544

7.  Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial.

Authors:  Bernard Escudier; Anna Pluzanska; Piotr Koralewski; Alain Ravaud; Sergio Bracarda; Cezary Szczylik; Christine Chevreau; Marek Filipek; Bohuslav Melichar; Emilio Bajetta; Vera Gorbunova; Jacques-Olivier Bay; Istvan Bodrogi; Agnieszka Jagiello-Gruszfeld; Nicola Moore
Journal:  Lancet       Date:  2007-12-22       Impact factor: 79.321

8.  Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study.

Authors:  Ezra E W Cohen; Lee S Rosen; Everett E Vokes; Merrill S Kies; Arlene A Forastiere; Francis P Worden; Madeleine A Kane; Eric Sherman; Sinil Kim; Paul Bycott; Michael Tortorici; David R Shalinsky; Katherine F Liau; Roger B Cohen
Journal:  J Clin Oncol       Date:  2008-06-09       Impact factor: 44.544
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.